| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Myriad Genetics Inc
Myriad Genetics Inc
NASDAQ:MYGN
Myriad Genetics Inc
PP&E Net
Myriad Genetics Inc
PP&E Net Peer Comparison
ABBV
GILD
AMGN
VRTX
REGN
Competitive PP&E Net Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Myriad Genetics Inc
NASDAQ:MYGN
|
PP&E Net
$177.4m
|
CAGR 3-Years
19%
|
CAGR 5-Years
25%
|
CAGR 10-Years
18%
|
|
|
Abbvie Inc
NYSE:ABBV
|
PP&E Net
$5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
9%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
PP&E Net
$5.3B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
15%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
PP&E Net
$6B
|
CAGR 3-Years
7%
|
CAGR 5-Years
2%
|
CAGR 10-Years
1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
PP&E Net
$1.5B
|
CAGR 3-Years
4%
|
CAGR 5-Years
13%
|
CAGR 10-Years
7%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
PP&E Net
$4.2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
10%
|
CAGR 10-Years
22%
|
See Also
What is Myriad Genetics Inc's PP&E Net?
PP&E Net
177.4m
USD
Based on the financial report for Mar 31, 2024, Myriad Genetics Inc's PP&E Net amounts to 177.4m USD.
What is Myriad Genetics Inc's PP&E Net growth rate?
PP&E Net CAGR 10Y
18%
Over the last year, the PP&E Net growth was -13%. The average annual PP&E Net growth rates for Myriad Genetics Inc have been 19% over the past three years , 25% over the past five years , and 18% over the past ten years .
You don't have any saved screeners yet
